These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2868474)

  • 1. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
    Frecska E; Perényi A; Bagdy G; Révai K
    Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
    Mignot E; Laude D; Elghozi JL
    J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
    Frecska E; Bagdy G; Perenyi A; Arato M; Degrell I; Mogyorosy Z
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):291-5. PubMed ID: 2577713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of indices of central dopaminergic functions in man.
    Bagdy G; Arató M; Baraczka K; Fekete MI
    Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission.
    Garrett MC; Soares-da-Silva P
    J Neurochem; 1992 Jan; 58(1):101-6. PubMed ID: 1309230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.
    Davis KL; Faull KF; Hollister LE; Barchas JD; Berger PA
    Psychopharmacology (Berl); 1981; 72(2):155-60. PubMed ID: 6782605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid.
    Ebinger G; Michotte Y; Herregodts P
    J Neurochem; 1987 Jun; 48(6):1725-9. PubMed ID: 3572399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy.
    van Kammen DP; van Kammen WB; Mann LS; Seppala T; Linnoila M
    Arch Gen Psychiatry; 1986 Oct; 43(10):978-83. PubMed ID: 3753162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine.
    Mignot E; Laude D
    J Neurochem; 1985 Nov; 45(5):1527-33. PubMed ID: 2864397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
    Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
    Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury.
    Wagner AK; Ren D; Conley YP; Ma X; Kerr ME; Zafonte RD; Puccio AM; Marion DW; Dixon CE
    J Neurosurg; 2007 Apr; 106(4):538-47. PubMed ID: 17432702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent determination of brain dopamine and 5-hydroxytryptamine turnovers in individual freely moving rats using repeated sampling of cerebrospinal fluid.
    Hutson PH; Sarna GS; Kantamaneni BD; Curzon G
    J Neurochem; 1984 Jul; 43(1):151-9. PubMed ID: 6202842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine metabolites in human brain.
    Wilk S; Stanley M
    Psychopharmacology (Berl); 1978 Apr; 57(1):77-81. PubMed ID: 96472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine metabolites in rat cisternal cerebrospinal fluid: major contribution from extrastriatal dopamine neurones.
    Hutson PH; Curzon G
    J Neurochem; 1986 Jan; 46(1):186-90. PubMed ID: 2415677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment.
    Barkai AI; Kowalik S; Reches A
    Psychopharmacology (Berl); 1984; 84(3):352-5. PubMed ID: 6083575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.